Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 7/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30135168 | 0.86 | CYP2C19 (0.46) | CYP2C19HTR6DRD2HTR2AKLKB1 | |
| SCHEMBL31668585 | 0.84 | CYP2C19 (0.44) | CYP2C19HTR6DRD2HTR2AKLKB1 | |
| SCHEMBL31668605 | 0.80 | CYP2C19 (0.45) | CYP2C19HTR6DRD2HTR2AKLKB1 | |
| SCHEMBL1672537 | 0.78 | CYP2C19 (0.58) | CYP2C19HTR6DRD2HTR2AL3MBTL1 | |
| SCHEMBL31668592 | 0.77 | CYP2C19 (0.44) | CYP2C19HTR6DRD2HTR2APIK3C3 | |
| SCHEMBL30135143 | 0.77 | CYP2C19 (0.51) | CYP2C19HTR6DRD2HTR2APIK3C3 | |
| SCHEMBL25322767 | 0.77 | CYP2C19 (0.46) | CYP2C19HTR6DRD2HTR2APIK3C3 | |
| SCHEMBL31668597 | 0.77 | CYP2C19 (0.46) | CYP2C19HTR6DRD2HTR2APIK3C3 | |
| SCHEMBL31668594 | 0.77 | CYP2C19 (0.46) | CYP2C19HTR6DRD2HTR2APIK3C3 | |
| SCHEMBL30543160 | 0.77 | CYP2C19 (0.46) | CYP2C19HTR6DRD2HTR2APIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | CYP2C19 4454/4885HTR6 3372/4885DRD2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.